Enliven Therapeutics, Inc.
JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.
Derynck Mika K sold 158,795 shares of Enliven Therapeutics, Inc. (ELVN) at $60.21 ($9.56M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
Enliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ELVN (Enliven Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ELVN coverage spans financial news, insider activity and earnings.
In the last 30 days, ELVN insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($555K). The most active reporter was Collins Helen Louise, CHIEF MEDICAL OFFICER, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst upgrade and high price target suggest strong upside potential.
This is a routine insider sale disclosure with no new operating or guidance catalyst, but it can still affect near-term sentiment and positioning.
Clinical and regulatory progress (Phase 1 efficacy, Fast Track, FDA alignment on Phase 3 design) plus extended cash runway into 2030.
Capital raise plus clinical timeline can be supportive, but dilution risk may cap upside near-term.
This is a routine insider sale under a 10b5-1 plan, with no new operational or financial catalyst disclosed.
AlphAI scores every news story that mentions ELVN with an AI model for sentiment and relevance, and aggregates insider trades from Enliven Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.
2 min readDerynck Mika K sold 158,795 shares of Enliven Therapeutics, Inc. (ELVN) at $60.21 ($9.56M total) on 2026-08-04 under a Rule 10b5-1 trading plan.
1 min readEnliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme
6 min readBiotech stocks hit 52-week highs on July 16, 2026 ahead of quarterly reports or a conference. CareDx (CDNA) rose to a 52-week high of $40.38% and reported Q1 revenue of $118M. Integra LifeSciences (IART) reached $20.26, with Q1 revenue $391.9M. Bioventus (BVS) hit $12.53, Q1 revenue $132M. Enliven Therapeutics (ELVN) hit $53.89 after a ~$460M public offering.
5 min readKunkel Lori Anne sold 10,000 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $50.49 ($49.98–$50.84, $0.50M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
2 min readEnliven Therapeutics director Lori Anne Kunkel sold 10,000 shares for about $345,000 on June 5, 2026, per an SEC Form 4. The weighted average sale price was $34.54; she reduced her direct holdings by 16% to 51,884 shares. The sale followed a Rule 10b5-1 plan adopted March 6, 2026. Shares had risen 62.4% over the prior year.
4 min readOn June 22, 2026, Orbimed Advisors, a 10% owner of Enliven Therapeutics (ELVN), disclosed an indirect sale of 860,123 shares for about $39.0 million, according to an SEC Form 4. The shares were sold at a weighted average price of $45.36. The sale was 11.6% of Orbimed’s prior indirect holdings; remaining shares are held via OrbiMed funds.
4 min readORBIMED ADVISORS LLC sold 860,123 indirectly-held shares of Enliven Therapeutics, Inc. (ELVN) at an average of $45.36 ($45.00–$45.38, $39.01M total) across 4 trades on 2026-06-22.
2 min readEnliven Therapeutics (Nasdaq: ELVN) moved its corporate headquarters from Boulder, Colorado to Burlingame, California, according to SEC prospectus filings and a company spokesperson. The firm says it keeps operations in Boulder. In June it reported $452.4 million in cash and expects runway into H1 2029, with ELVN-001 CML trial phase set for late 2026.
3 min readORBIMED ADVISORS LLC sold 281,408 indirectly-held shares of Enliven Therapeutics, Inc. (ELVN) at $45.02 ($12.67M total) across 2 trades on 2026-06-15.
1 min read
